SCHEMBL4008933

SCHEMBL4008933

CC(C)(C)OC(=O)N1CCC(CCCn2ccc3cc(Br)cnc32)CC1

nearest known ligand 0.47

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 14/20 0.47
FAAH O00519 1/20 0.46
FNTA P49354 1/20 0.46
FNTB P49356 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19461156 0.90 FNTA (0.46) GPR119FAAHFNTAFNTB
SCHEMBL4173927 0.88 GPR119 (0.46) GPR119FAAH
SCHEMBL20476727 0.78 GPR119 (0.43) GPR119FAAH
SCHEMBL4166408 0.77 HRH4 (0.48) GPR119
SCHEMBL18917768 0.77 STK17B (0.44)
SCHEMBL17063253 0.75 FPR2 (0.48) GPR119
SCHEMBL19461048 0.74 PIK3CA (0.43) GPR119FAAHFNTAFNTB
SCHEMBL947729 0.74 FAAH (0.56) GPR119FAAH
SCHEMBL21268753 0.74 JAK3 (0.43) GPR119FAAH
SCHEMBL31496247 0.73 GPR119 (0.48) GPR119FAAHFNTAFNTB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8084466-B2 Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor JANSSEN PHARMACEUTICA NV (BE) 2011-12-27 US disclosed
WO-2009079001-A1 BICYCLIC HETEROARYL-SUBSTITUTED IMIDAZOLES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2009-06-25 WO disclosed
US-20090156613-A1 Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor KINDRACHUK DAVID E 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156613-A1 Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor HRH4, HRH3, HRH1 GPR119 377/4885FAAH 345/4885FNTA 3601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.